Wedbush Maintains Outperform on Sangamo Therapeutics, Lowers Price Target to $10
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Andreas Argyrides has maintained an 'Outperform' rating on Sangamo Therapeutics (NASDAQ:SGMO), but lowered the price target from $16 to $10.
August 11, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics' price target has been lowered from $16 to $10 by Wedbush, although the 'Outperform' rating is maintained.
The lowering of the price target by a significant amount could lead to a negative sentiment among investors, potentially causing a short-term drop in the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100